In 2022, Sanchez et al. [7] demonstrated elevated serum CEA levels (cutoff value, 5 IU/ml) was observed in patients with locally advanced or metastatic (both p < 0.001) ICC when compared to those with earlier − stage, liver − confined disease. This evidence concerns the gene CEACAM5 and intrahepatic cholangiocarcinoma.